MHB036C / Minghui Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MHB036C / Minghui Pharma
CTR20231246: An open-label, dose-escalation and dose-expansion phase I/II clinical study of the safety/tolerability, pharmacokinetics, and efficacy of injectable MHB036C in patients with advanced malignant solid tumors

Ongoing
1/2
48
China
MHB036C - Minghui Pharma
Minghui Pharmaceutical (Hangzhou) Co., Ltd
Advanced malignant solid tumors
 
 
NCT06373406: A Study of MHB036C for Advanced Solid Tumor

Recruiting
1/2
200
RoW
MHB036C
Minghui Pharmaceutical (Hangzhou) Ltd
Advanced Solid Tumor
08/24
12/24
NCT05642949: Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors

Not yet recruiting
1/2
400
RoW
MHB036C
Minghui Pharmaceutical Pty Ltd
Advanced Solid Tumor
12/25
06/26

Download Options